Pharmaceutical sector is blooming at subsequently than ever being imagined. And only few companies proved themselves worthy of it. Meet, a CMIC, Inc. leading CRO (Contract Research Organization) and a provider specialized in bioanalytical services, whose cutting-edge capabilities and sophisticated expertise in various aspects helped it achieve a greater stature in the business. Its bioanalytical services are in support of TK/PK/PD Biomarker studies for pre-clinical and clinical developments. It ﬁrmly focuses and holds expertise in bioanalytical method development, method validation/qualiﬁcation and study sample analysis for small, large molecules and Oligonucleotide. The “CMIC” name originally stood for “Current Medical Information Center”, and the company remains committed to the advancement of medicines and healthcare revolution. As a strategic drug development partner, CMIC helps sponsors to overcome challenges in bioanalysis with expertise, rapid data turn-around-time, and high-quality customer services.
“Our vision is to advance the innovation of products and solutions that will empower people worldwide to achieve greater health and well-being”
The company states its core values intercepted through, W & 3C;
- WELLBEING: Fully Live Every Moment
- Challenge: Liberate opportunity by changing our vantage point
- Change: Transform without seeking refuge in conventional wisdom
- Communication: Proactively reach out to sponsors, people and society
The Story behind CMIC
CMIC Inc. originated from CMIC Group, which is the very ﬁrst and largest Contract Research Organization (CRO) in Japan. Contract research organizations (CROs) have become an integral part of drug discovery and development to support sponsors research needs, expedite timelines and provide an extension of technical and scientiﬁc support. CMIC has worked with the top 10 global pharma companies and has been involved in and supported more than 80% of new drug development in Japan.
CMIC, Inc. was established as a strategic cornerstone for CMIC Group’s North America growth. It has the vision to provide a solution service as “Pharmaceutical Value Creator” (PVC) that encompasses an entire value-chain of pharmaceutical companies. The company has been the top bioanalysis CRO in oligonucleotide therapeutics (Oligo) development for nearly a decade with strong proven expertise. It also oﬀers 30+ years of experience in conventional & small molecule and are also signiﬁcantly expanding its capabilities in large molecule and biomarker Bioanalysis. On account being diﬀerent from other companies, it is leading bioanalysis CRO in oligonucleotide therapeutics (Oligo) as well as very ﬂexible and agile with quick turn-around time on all services oﬀered, which is not possible by large CROs. In addition, CMIC, Inc. together with the rest of CMIC Group has signiﬁcant scientiﬁc publications and whitepapers and had been the integrated players f supporting various drug development eﬀorts.
A Glimpse into Jenny’s Life Jenny
Lin, Chief Operating Oﬃcer and Board Member. She holds 26 years of executive/lab management experience in bioanalytical and analytical laboratory operations in support of drug discovery, pre-clinical and clinical drug development. Moreover, she is proﬁcient in GLP, GMP, GCP, OECD, ICH and 21 CFR part 11 regulations and in business strategic planning and execution. Her expertise includes building organizational quality system, staﬀ training, bioanalytical/analytical method development/validation, bioanalytical sample analysis, analytical development for CMC submission, chromatography puriﬁcation, stability studies, reference standard certiﬁcation, QC support for GMP manufacture. She has been also a selected member for Global Bioanalysis Consortium (GBC) making recommendations for global Bioanalysis harmonization. She serves as editorial board member for peer reviewed journal and chair for international conferences.
Besides, she is an author and co-author for approximately 40 publications, white papers and presentations and is the inventor of 7 issued US patents. Jenny earned her BS in Analytical Chemistry at Peking University and her MS in Medicinal Chemistry at University of Connecticut. She is a member of the American Society of Mass Spectrometry (ASMS), American Association of Pharmaceutical Scientists (AAPS), American Chemical Society (ACS), National Association of Professional Woman (NAPW) and Global CRO Council (GCC).
Future of CMIC
CMIC and the CREED as corporate philosophy, consists of Wellbeing, Challenge, and Communication (W&3Cs). The company has been applying these items to continuously evolve itself in line with market changes, and will do so in the future. Moreover, by further expanding from the current “Pharmaceutical Value Creator” (PVC) business model, the company has an aspiration to become a “Personal Healthcare Value Creator” (PHVC) to contribute for and to address to the up-coming personalized medicine and individual patient quality of life.